ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,1163
0,00%
Bitcoin
63.132,64
-0,95%
Brent Oil
88,165
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) Notícias

IMMP

Immutep (IMMP)

Immutep Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMMP
DataHoraFonteTítuloCódigoCompanhia
24/04/202409:00GlobeNewswire Inc.Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort BNASDAQ:IMMPImmutep Ltd
18/04/202409:00GlobeNewswire Inc.Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761NASDAQ:IMMPImmutep Ltd
17/04/202409:00GlobeNewswire Inc.Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
05/03/202410:00GlobeNewswire Inc.Immutep Announces First Clinical Data from 90mg Dosing of EftiNASDAQ:IMMPImmutep Ltd
30/01/202418:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
30/01/202410:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q2 FY24NASDAQ:IMMPImmutep Ltd
04/01/202410:00GlobeNewswire Inc.First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial CancerNASDAQ:IMMPImmutep Ltd
21/12/202310:00GlobeNewswire Inc.Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
07/12/202310:00GlobeNewswire Inc.Immutep Receives A$2.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
22/11/202310:00GlobeNewswire Inc.Immutep Announces Site Expansion for INSIGHT-003 Phase I TrialNASDAQ:IMMPImmutep Ltd
09/11/202310:00GlobeNewswire Inc.Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNASDAQ:IMMPImmutep Ltd
06/11/202310:00GlobeNewswire Inc.Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
03/11/202313:00GlobeNewswire Inc.Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
02/11/202309:00GlobeNewswire Inc.Immutep to Participate in November Investor EventsNASDAQ:IMMPImmutep Ltd
31/10/202309:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY24NASDAQ:IMMPImmutep Ltd
25/10/202309:00GlobeNewswire Inc.Immutep receives ~A$1.13 million R&D Tax IncentiveNASDAQ:IMMPImmutep Ltd
24/10/202309:00GlobeNewswire Inc.Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
23/10/202309:00GlobeNewswire Inc.Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
16/10/202309:00GlobeNewswire Inc.Immutep Announces Publication of Abstracts at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
03/10/202309:00GlobeNewswire Inc.Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNASDAQ:IMMPImmutep Ltd
21/09/202309:00GlobeNewswire Inc.Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseNASDAQ:IMMPImmutep Ltd
05/09/202310:00GlobeNewswire Inc.Immutep to Participate in September Investor ConferencesNASDAQ:IMMPImmutep Ltd
01/08/202309:00GlobeNewswire Inc.Immutep Receives Positive Scientific Advice from European Medicines AgencyNASDAQ:IMMPImmutep Ltd
31/07/202309:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY23NASDAQ:IMMPImmutep Ltd
31/07/202309:00GlobeNewswire Inc.Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023NASDAQ:IMMPImmutep Ltd
28/07/202309:00GlobeNewswire Inc.First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
28/06/202307:02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMMPImmutep Ltd
27/06/202309:00GlobeNewswire Inc.Immutep Completes A$80 Million Capital RaiseNASDAQ:IMMPImmutep Ltd
27/06/202309:00GlobeNewswire Inc.Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway InhibitorNASDAQ:IMMPImmutep Ltd
20/06/202309:00GlobeNewswire Inc.Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3NASDAQ:IMMPImmutep Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMMP

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
MATD3
Hospital Mater Dei S.A ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
GOLL4
GOL PN
BOV
PDTC3
Padtec ON
BOV
OIBR3
OI ON
BOV
PDGR3
PDG REALT ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
UNIP6
UNIPAR PNB
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados